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ABSTRACT  
Clostridioides (formally Clostridium) difficile is a medically relevant pathogen pertinent 
to infectious disease research. C. difficile is distinctly known for its ability to produce two toxins, 
enterotoxin A and cytotoxin B, and the propensity to colonize the mammalian gastrointestinal 
tract. It is known that metabolism is tightly correlated with sporulation in endospore producers 
such as C. difficile, but an interesting and novel regulatory relationship found by the Ivey lab has 
yet to be understood. The relationship explored in this study is observed between the sporulation 
factor, SpoIIE, which represses expression of an ABC peptide transporter, app. In this study, two 
primary approaches were taken in order to investigate this interaction. The first method involved 
directly mutating the gene for SpoIIE in attempt to understand which portion of the gene is 
crucial for retaining protein functionality, in this case, the repression of app. The two genes of 
interest were readily available on their own individual plasmids, which easily allowed for 
mutagenesis experimentation before transformation into E. coli. The plasmid with app was 
constructed to include a fluorescent probe, allowing the relative level of repression to parallel the 
qualitative measurement of fluorescence. On the SpoIIE containing plasmid, missense point 
mutations, done using PCR site-directed mutagenesis, and a large deletion of the SpoIIE protein 
transmembrane anchor, done by endonuclease restriction digest, were performed in pursuit of 
this investigative method. The secondary approach was to computationally model the SpoIIE 
protein structures resultant of the genetic mutations done in vitro. Side-by-side images of the 
predicted mutant models produced from the experimentally preferred algorithm were compared 
to the wildtype SpoIIE model. The visual analysis of the structures and the comparison of 
various algorithms is anticipated to be insightful for not only this project, but future exploration 
into SpoIIE as a multifunctional protein within C. difficile.  
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I. INTRODUCTION 
I.1. Infectious Diseases: an overview 
Infectious diseases are often thought of as agents with unknown origins infiltrating the 
civilized world, but in actuality, “Infectious Disease” is a term that describes a vast number of 
pathogens. The study of infectious diseases involves a complex network of dynamics observed 
between the host and parasite and is therefore inherently multidisciplinary (Engering et al., 
2013). This field of research relies on biologists, ranging from molecular and microbial to 
ecological and clinical, in order to develop a comprehensive understanding of an infection. In 
any clinical context, whether that be pharmaceutical treatment, epidemiological trends, or 
prevention medicine, the fundamental three-way interactions between the host, parasite and their 
physical environment must be considered.   
Infectious disease research is centralized around the relationship between the parasite and 
its host. Parasitism is an essential biological relationship and one of the most ubiquitous life 
strategies on Earth, as all living organisms are parasitized by at least one other species (Albert et 
al., 2002; Balloux & van Dorp, 2017). Parasite is a broad term that can be further divided into 
five major types: helminth, fungus, protozoan, bacteria, and viruses (Albert et al., 2002; Janeway 
et al., 2001; Kilpatrick & Altizer 2010). Prion is occasionally listed as a sixth category depending 
upon the source, as they are infectious proteins but not parasites (Albert et al., 2002; Barreto et 
al., 2006). More specifically, a pathogen is a parasite that causes disease to its host, whereas by 
comparison few parasites co-exist symbiotically with their hosts in the absence of disease 
(Balloux & van Dorp, 2017; Barreto et al., 2006; Casadevall & Pirofski 2000; Kilpatrick & 
Altizer 2010). In order to survive, pathogens must colonize a host, subvert both innate and 
adaptive immune responses, replicate, and lastly… spread to subsequent hosts (Albert et al., 
2002; Janeway et al., 2001).  
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By definition, disease describes a disorder in structure or function, especially alongside 
the production of explicit and identifiable symptoms (Balloux & van Dorp, 2017; Kilpatrick & 
Altizer 2010). Often times, disease symptoms presented by an infection aid in the transmission to 
the next host (Albert et al., 2002). For example, the common cold, caused by the rhinovirus, 
produces excess mucous along with sneezing and coughing; actions that aim to aerosolize viral 
particles in hopes of inhalation by another host to exploit (Jacobs et al., 2013). Many diseases 
present in the human population are not classified as infectious, but are rather inherited or 
congenital, one of the most common being cardiovascular disease (Mc Namara et al., 2019). 
Contrastingly, infectious diseases are caused by transmissible and communicable pathogens 
(Barreto et al., 2006). This defining quality of being “transmissible” allows for the analysis of 
how pathogens are maintained and transmitted within a host population, which often times have 
significant clinical implications. Again, emphasizing that understanding these large-scale 
infection dynamics is vital and parallel to the analysis of molecular interactions.  
Not all infectious diseases arise from the untamed wilderness in spillover events. In fact, 
the majority of human pathogens live and thrive in the same environment as us; their hosts 
(Dunn et al., 2010). Common human pathogens can be isolated from nearly any public space. 
The outdoor environment is home to numerous potential pathogens in the soil such as 
Toxoplasmosis gondii and Pseudomonas aeruginosa, while streams can be home to microbes 
such as Giardia lamblia and Legionella pneumonia (Gao et al., 2016; Green et al., 1974; 
McClung et al., 2017). Raw and unwashed food found in the produce section from a market is an 
ideal environment for Escherichia coli or Listeria monocytogenes (Zeng et al., 2014; Zhang et 
al., 2018). Industrial facilities, such as a sewage treatment plants, are often the environment for 
pathogens such as Enterococcus faecalis and Proteus vulgaris (Cyprowski et al., 2018). Even 
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medical settings, such as hospital rooms (places optimistically thought to be sterile) prove to be a 
niche environment for opportunistic pathogens such as methicillin-resistant Staphylococcus 
Aureus (MRSA) and C. difficile (Hassoun et al., 2017; Walters et al., 1983). Pathogens are 
evidently omnipresent, but their pervasiveness is chiefly controlled by host availability and 
transmission routes (Kilpatrick & Altizer 2010). 
The prevalence of all pathogens is largely dependent on and limited by their mode of 
transmission (Antonovics et al., 2017; Barreto et al., 2006; Dunn et al., 2010). There are five 
modes of pathogen transmission: direct contact, inhalation, fecal-oral, vector-borne and fomite 
(Antonovics et al., 2017). Direct contact infections occur through an open wound or mucous 
membrane, such as with sexually transmitted diseases like Chlamydia trachomatis (Phillips 
2019). Inhalation transmission is seen in respiratory viruses like coronaviruses, or SARS-CoV-2 
(Kucharski et al., 2020). The fecal-oral transmission route is utilized by pathogens like Vibrio 
cholerae or Salmonella enterica; the culprits behind many cases of food poisoning (Diard & 
Hardt 2017; Rinaldo et al., 2017). Vector-borne pathogens are transmitted to hosts via arthropods 
like ticks and mosquitos, some of these being Borrelia burgdorferi, Plasmodium falciparum and 
all flaviviruses (Rossati et al., 2016; Schorderet-Weber et al., 2017; Leitner et al., 2015). The 
fifth mode, fomite, uniquely requires a secondary mode of transmission, such as ingestion 
(Antonovics et al., 2017). The term fomite refers to objects likely to carry microbes that have the 
ability to persist in the environment for prolonged periods of time in the absence of a host 
(Alberts et al., 2002). Endospore producers commonly exist in their dormant spore-form in the 
environment on a fomite, and then germinate into vegetative cells once being either ingested or 
inhaled by a susceptible host (Deakin et al., 2012; Saujet et al., 2013). C. difficile is an archetypal 
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pathogen that employs this evolutionarily advantageous method of transmission (Paredes-Sabja 
et al., 2014).  
In the case of microparasites, such as bacteria, the host can additionally be thought of as 
the “environment” (Kilpatrick & Altizer 2010). With the exception of fomite transmission, most 
parasites cannot survive extensively in the exterior environment without a host. Parasites are 
entirely dependent upon their hosts for protection and nutrients in order to subsist (Albert et al., 
2002; Kilpatrick & Altizer 2010). Gastrointestinal pathogens, transmitted through the fecal-oral 
route, are ideal examples when considering how the host can double as the environment.  
The human body’s temperature, in combination with an anaerobic setting and a radical 
drop in pH due to hydrochloric acid found in the stomach, create a unique environment for 
invading intestinal pathogens to endure (Fimlaid et al., 2015). Furthermore, as many studies have 
published, the human microbiome is a notably complex ecosystem within itself, as the colon is 
home to upwards of five-hundred bacterial species alone (Jandhyala et al., 2015; Lozupone et al., 
2012). This intestinal environment proves to be a tricky one for attacking pathogens as they face 
high temperatures, little oxygen, an acidic pH, and the normal gut flora as powerful resource 
competitors (Lozupone et al., 2012). The successful invaders of the gastrointestinal tract have 
shown to be both opportunistic and resilient.  
Opportunistic pathogens are defined in medical literature as organisms that “become 
pathogenic following a perturbation to their host” (Brown et al., 2012). Nosocomial infections, 
ones originating from hospitals, are conventionally and fundamentally understood to be driven 
by opportunistic pathogens (Fimlaid et al., 2015). Hospitals are home to the weakest and most 
susceptible host population while simultaneously housing some of the most aggressive and 
resilient pathogens. Numerous hospital residents are recipients of heavy antibiotics following a 
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range of routine procedures (Rupnik et al., 2009). In many cases, these antibiotic therapies 
protect patients against subsequent infections, but inadvertently, this makes patients intestinally 
available for opportunistic colonization as normal gut flora become deficient (Barreto et al., 
2006; Brown et al., 2012). Due to their unique infection dynamics within a specific niche, an 
entire division of infectious disease research is dedicated to nosocomial infections (Alberts et al., 
2002; Casadevall & Pirofski 2000). C. difficile is the ideal model of an opportunistic, nosocomial 
pathogen as these intestinal infections almost exclusively originate from healthcare settings 
(Deneve et al., 2009; Dodson & Borriello 1996). 
Aside from being opportunistic, C. difficile is also considered to be a highly resilient 
pathogen because of its ability to produce endospores (Deakin et al., 2012; Fimlaid et al., 2015). 
As briefly mentioned, the production of endospores allows for C. difficile to withstand a variety 
of harsh environmental factors. Spores can exist on various medical surface fomites as they are 
resistant to desiccation and disinfectants (Lawley et al., 2009). These metabolically dormant 
spores can then be unintentionally ingested by abundantly available and susceptible hosts 
(Paredes-Sabja et al., 2014). Not only do the spores successfully evade death by disinfectants, 
they also have the uncanny ability to survive the stomach pH, and then germinate in the intestinal 
tract (Fimlaid et al., 2015). Successful colonization of the intestinal tract by C. difficile is 
primarily seen in the absence of resource competitors, or the normal gut microbes removed 
through antibiotic therapy (Walters et al., 1983).  
The aforementioned infection dynamics are multifaceted and highly distinctive to this 
system. The transmission route, niche susceptible host population, and evolutionary reproductive 
tactics, make C. difficile a fascinating organism in which to study infection at a molecular scale. 
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C. difficile is a medically relevant pathogen with unique microbial properties that make it an 
interesting model for infectious disease studies. 
I.2. C. difficile: history and facts 
C. difficile is a gram positive, anaerobic, endospore producing bacilli that is virtually 
endemic to hospitals and their population of vulnerable hosts (Redelings et al., 2007). In the 
context of this infectious disease, a vulnerable host is one who has deficient normal intestinal 
flora or a weakened immune system (Bartlett & Gerding 2008). Generally, these are 
characteristics resultant of both broad-spectrum antibiotics and chemotherapy, two commonly 
received medical treatments, which have aided in the creation of a niche population of 
susceptible hosts for C. difficile in the medical setting (Murphy et al., 2012; Redelings et al., 
2007). Furthermore, transmission within the hospital patient host population, demonstrates 
horizontal and density-dependent transfer between individuals (McDonald 2013). Horizontal 
transmission indicates that any individual within the identified host population can become 
infected, while density-dependent refers to the statistical increase in incidence seen with an 
increase in available hosts (Kilpatrick & Altizer 2010; McDonald 2013).  
C. difficile is the reigning cause of nosocomial gastrointestinal diseases and a leading 
causative agent for antibiotic associated diarrhea (AAD) (15-25% of all reported cases) in 
Western and European countries for nearly five decades (Bouza et al., 2012; Dubberke & Olsen 
2012; Freeman et al., 2010). In the United States alone, the C. difficile mortality rate reported an 
increase of 5.7 per million in 1999, to a rate of 23.7 per million just five years later in 2004 
(Redelings et al., 2007). C. difficile remains a prevalent nosocomial pathogen because of its 
ability to evade antimicrobials through endospore production, seen both inside the host and in the 
exterior environment (Fimlaid et al., 2015). Despite being anaerobic, C. difficile persists without 
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a host in an oxygenic environment by existing as spore fomites (Fimlaid et al., 2015; Pereira et 
al., 2013; Underwood et al., 2009). These infectious spores survive surface disinfectants and 
germinate into vegetative cells after ingestion (Casadevall & Pirofski 2000; Janeway et al., 
2001). This is representative of the fecal-oral transmission route as discussed above. Within the 
host, that same ability to produce spores also contributes to the survival of C. difficile despite the 
use of antibiotics aimed at clearing the infection (Walters et al., 1983). 
The disease spectrum seen in C. difficile infections is highly variable (Bartlett & Gerding 
2008; Deneve et al., 2009). Symptoms range from mild diarrhea and colitis, to severe toxic 
megacolon and sepsis (Bartlett & Gerding 2008; Carman et al., 2011). The most severe cases 
result in antibiotic-associated pseudomembranous colitis (AA PMC), a symptom observed only 
after established colonization in the colon of patients under heavy antibiotic therapy (Lawley et 
al., 2009; Walters et al., 1983). PMC often presents with accompanying symptoms such as 
intestinal distention, colitis, abdominal pain, and severe diarrhea (Reinke & Messick 1994; 
Surawicz & McFarland 1999). If improperly treated, PMC can further progress into toxic 
megacolon and present complications such as organ failure and sepsis (Borriello, 1990; Dodson 
& Borriello, 1996; Surawicz & McFarland, 1999; Deneve et al., 2009). As seen with most 
pathogens, the course of infection produces symptoms or altered “host behavior” that aim to 
increase the likelihood of transmission (Antonovics et al., 2017; Casadevall & Pirofski 2000). 
The pathogenicity of C. difficile results in heavy diarrhea and spore shedding into the 
environment; a host behavior change that propagates the pathogen’s spread (Engering et al., 
2013). Not only does this elucidate how C. difficile dominates as a resilient and opportunistic 
nosocomial pathogen, but this emphasizes the importance of preventative measures for health 
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care workers (i.e. gloves, handwashing, etc.) in order to thwart successive spreading to additional 
patients (Kampf et al., 2009; Lessa et al., 2012; Paredes-Sabja et al., 2014).  
Antibiotic resistance is a growing topic of concern, particularly for nosocomial pathogens 
such as methicillin-resistant Staphylococcus aureus (MRSA) and C. difficile (Lawley et al., 2009; 
Walters et al., 1983). Their overexposure to antimicrobials (environmental disinfectants and broad-
spectrum antibiotics) has led to their adaptation to withstand such treatments and the ensuing 
emergence of highly virulent strains (Deneve et al., 2009; Fawley et al., 2007; Lawley et al., 2009). 
Multi-drug resistant organisms (MDROs) no longer respond to traditionally effective medications 
which poses a substantial limitation for patient care and treatment (Walters et al., 1983). Since C. 
difficile is already an aggressive and invasive pathogen, there are ongoing programs that monitor 
the existence and prevalence of specific strains, as well as precautions that are taken by health 
professionals to prevent or delay the appearance of hyper-virulent strains (Lessa et al., 2012; 
Walters et al., 1983). One being the intentional avoidance of vancomycin (a powerful broad-
spectrum antibiotic) to treat C. difficile patients in order to preclude the development of 
vancomycin-resistant strains (Surawicz & McFarland, 1999; Walters et al., 1983). Not only does 
C. difficile exhibit advantageous transmission tactics that make it incredibly successful in 
healthcare settings, but its pathogenicity and ability to produce toxins play a major role in overall 
virulence (Di Bella et al., 2016; Lessa et al., 2012; Paredes-Sabja et al., 2014). 
 
I.3. Pathology: metabolism and toxicity 
After accidental ingestion by a susceptible host, C. difficile spores resist destruction by 
gastric acid and germinate after reaching the small intestines (Lessa et al., 2012; Paredes-Sabja et 
al., 2014). Once in its vegetative and metabolically active state, C. difficile colonizes mammalian 
intestines in the absence of normal gut flora, typically after long term antibiotic usage (Depestel 
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& Aronoff 2013; Lessa et al., 2012). With the lack of resource competitors, C. difficile 
proliferates and dominates the intestinal microbial population (Depestel & Aronoff 2013). 
Following successful colonization, C. difficile adheres to intestinal epithelial cells and produces 
two toxins which heavily influence the course of the infection (Borriello 1990; Borriello et al., 
1990). These toxins play an insidious role during a C. difficile infection and a plethora of studies 
have addressed these toxins, their structures, and the devious effect they have on the host 
(Depestel & Aronoff 2013; Di Bella et al., 2016; Lessa et al., 2012; Taylor et al., 1981).  
The ability to adhere to the intestinal epithelium acts as an accessory virulence factor for 
C. difficile as it aids in toxin delivery and penetration (Di Bella et al., 2016; Karjalainen et al., 
1994). The destructive virulence factors underlying a C. difficile infection are two large 
exotoxins, toxin A and B, encoded by genes tcdA and tcdB within the chromosomal DNA 
pathogenicity locus (paloc) (Di Bella et al., 2016; Lessa et al., 2012). Toxin B was the first to be 
discovered and was initially named “cytotoxin” (Taylor et al., 1981). TcdB is a 250-270 kd 
cytotoxin that leads to depolymerization of actin and other cytoskeletal components in 
mammalian cell lines in vitro, resulting in the demise of cellular structure and function (Di Bella 
et al., 2016; Hecht et al., 1988; Ottlinger & Lin 1988). Toxin A is a 308 kb enterotoxin that 
tightly binds epithelial cell receptors, leading to fluid secretion, inflammation, and tissue necrosis 
(Just et al., 1995; Kelly et al., 1994).  Additionally, tcdA & tcdB glycosylate small Rho proteins 
using UDP-glucose as the sugar donor and lead to cytoskeleton disorganization (Deneve 
2009) Among common strains, toxin production increases as C. difficile enters the stationary 
growth phase, whereas hypervirulent strains also interestingly display toxin production during 
the exponential phase (Deneve et al., 2009; Freeman et al., 2010). 
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Being that C. difficile is an endospore forming bacteria, sporulation is another metabolic 
event also influencing the pathogen’s virulence. Sporulation occurs when vegetative growth is no 
longer metabolically favored, and both environmental and cellular signals initiate a complex 
cascade of activations ultimately leading to the production of spores (Edwards & McBride 2014; 
Saujet et al., 2013; Underwood et al., 2009). Epidemic strains of C. difficile, such as ribotypes 
001 and 027, even demonstrate an increase in sporulation capacity, reflected in their increased 
virulence (Fawley et al., 2007; Freeman et al., 2010). Spore production is controlled through the 
activation of sporulation factors which govern transcription factors, and ultimately up-regulation 
of the genes responsible for spore formation (Edwards & McBride 2014; Fimlaid et al., 2013; 
Paredes-Sabja et al., 2014; Pereira et al., 2013).  
The pathogenicity observed in C. difficile is multifaceted as it involves dynamics that 
must take into account metabolic processes such as spore formation and toxin production, both 
of which are direct links to the organism’s virulence. Metabolism in general is tightly correlated 
with the availability of nutrients and resource utilization (Casadevall & Pirofski 2000). As C. 
difficile is living in a peptide rich environment, the gastrointestinal tract, it can be inferred that 
successful interaction with the intestinal environment and subsequent cellular transport of 
peptides is essential for colonization.  
 
I.4. The relationship between SpoIIE and ABC peptide transporter, app 
 In previous experiments done by the Ivey lab, screens of genomic libraries were 
preformed in order to identify gene products regulating peptide transport in C. difficile. Studying 
cellular peptide transport can be insightful for understanding resource utilization and metabolism 
in the context of virulent organisms, which is why the preceding project was pursued. The 
central method used in these screenings involved the use of a green fluorescence protein (GFP), 
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which was fused onto the promoter region of the app (formerly opp) oligopeptide transporter. 
This allowed for the relative repression levels to be viewed as relative brightness, as the GFP 
gene, under the control of the app promoter, was repressed. Two proteins, MtlF and SpoIIE, 
were identified as transcriptional repressors based upon their reduced amount of fluorescence 
after screening, and investigating SpoIIE became the focal point of this research project. 
SpoIIE is a sporulation factor found in all gram-positive, spore-forming bacteria (Saujet 
et al., 2013). It is most aptly characterized in the model organism, B. subtilis, which is analogous 
to the C. difficile model discussed in this study. SpoIIE is a multifunctional protein directly 
involved in the regulation and timing of spore development through septum formation and 
activation of transcription factors (Barak et al., 1996; Carniol et al., 2005). SpoIIE has a TM 
domain of 10 helices on the N-terminus, a C-terminus phosphatase domain, and a central domain 
with ambiguous function (Arigoni et al., 1999; Carniol et al., 2005). The TM domain allows for 
SpoIIE membrane integration and localization, while the cytoplasmic phosphatase domain both 
catalyzes the dephosphorylation of anti-sigma factor SpoIIAA and also binds specific 
cytoskeletal proteins such as FtsZ and RodZ (Ben-Yehuda & Losick 2002; Lucet et al., 2000). 
SpoIIE exists as a dimer, and the dimerization of this protein is believed to play a role in the 
regulation and timing of the phosphatase domain activity (Arigoni et al., 2002). 
 The C-terminus portion of SpoIIE, or the phosphatase domain, has previously been 
crystallized and is more thoroughly studied than the remaining domains of SpoIIE as it belongs 
to a large family of PP2C serine phosphatases (Arigoni et al., 2002; Barak et al., 1996). In 
addition to the phosphatase domain, this cytoplasmic region contains a long alpha-helix which 
serves as the dimer interface while also indirectly interacting with the phosphatase domain via a 
helical hairpin referred to as the “switch” (Arigoni et al., 2002). The switch rotates upon 
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dimerization and activates the adjacent phosphatase region of SpoIIE (Arigoni et al., 2002; 
Carniol et al., 2005). Being that only the C-terminus of the B. subtilis SpoIIE protein has been 
crystallized, there is still much to be determined about the protein structure and function within 
the central and N-terminus domains, especially when directing this study back to the C. difficile 
model.  
 The peptide transporter, app, is an oligopeptide permease protein falling into the broad 
classification of an ABC transporter and ATP-binding cassette, which actively transports 
substrates such as peptides (Beis 2015; Locher 2016). App consists of five subunits, A, B, C, D 
and F, each with a specific role in the recognition, binding and ultimately transport of peptides 
(Steglich et al., 2018). Furthermore, each subunit of app has its own corresponding gene within 
the app locus (Arigoni et al., 2002). Curiously, the genes are divided and controlled by two 
promoters in opposite directions (Figure 1.1.). These promoters were mapped previously in the 
Ivey Lab. Studies with GFP fused to the promoter-containing locus revealed that SpoIIE 
represses appDF expression. The directness of the connection between SpoIIE expression and 
repression of appDF is unknown, and the first step to gathering an understanding of this 
regulatory relationship relies on investigating SpoIIE protein structure and function. This  
 
investigation is designed around evaluating mutations within critical domains of SpoIIE in order 
to assess the affects they have on function. 
Figure 1.1. App locus Image generated using Adobe Illustrator to edit a VectorNTI 
image. 
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Within the B. subtilis model, specific SpoIIE mutants have been created that are defective 
in one or all functions mentioned (Barak et al., 1996). Mutations targeting the switch exhibit 
defective phosphatase activity, while mutations targeting the alpha-helix prevent dimerization 
and therefore all subsequent protein function. Similar mutations have been targeted within the C. 
difficile SpoIIE protein sequence in order to understand the repression of appDF transcription 
discussed above. It is unknown whether the repression is direct, mediated, or whether 
phosphatase activity is required for repression to occur. The following project outlines the 
experimental design, both in vitro and in silico, and discusses the findings, their implications, 
and future research directions. 
I.5. Research aims 
In an attempt to understand the regulatory interaction observed between sporulation factor, 
SpoIIE, and the ABC peptide transporter, app, specific mutations can be made to SpoIIE in order 
to genetically investigate which portion of the gene is crucial for maintaining the regulatory 
function it has on appDF. This is an organized, molecular investigation into a specific genetic 
relationship that underlies essential pathogen characteristics such as metabolism, sporulation, toxin 
production, resource utilization and environment interaction. All of these features play a deliberate 
role in how C. difficile interacts with its host and environment and can therefore provide insight 
into the nature of this infectious disease. 
The following is the central hypothesis: If certain mutations within the gene for SpoIIE 
prove to be non-conservative and demonstrate a loss of protein structure and function, then it can 
be understood as to which specific portion of SpoIIE is essential for this regulatory interaction 
with peptide transporter, app. 
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In order to test this hypothesis, two principal research aims were pursued by implementing 
molecular genetics methods both in vitro and in silico. 
Research Aim 1. The first aim focuses on the genetic investigation of the regulatory 
properties of SpoIIE and what parts of the gene encoding SpoIIE, and the protein itself, are 
necessary for retaining this function. This aim was pursued using classical molecular biology 
techniques to mutate the SpoIIE gene and assess the subsequent protein functionality via 
fluorescence assay. 
Research Aim 2.  For the second aim, bioinformatics software was utilized to supplement 
work done in vitro and build computational models of SpoIIE. This research aim is important 
because it allows for a visual analysis of SpoIIE protein structure following the mutagenesis 
experimentation outlined in the first research aim. 
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II. GENETIC MUTANTS OF SPOIIE AND SCORING OF FUNCTIONALITY 
II.1. Introduction 
It is known that sporulation is coupled with metabolic pathways such as toxin production, 
but it remains to be understood why when expressed, this sporulation gene SpoIIE, represses the 
expression of the gene encoding peptide transporter, appDF, in C. difficile as was found by the 
Ivey lab. The correlation between active resource utilization and the metabolic event of sporulation 
is crucial to understanding this infectious disease and needs to be examined in the context of overall 
pathogenicity of C. difficile.  This curious relationship has yet to be investigated and could 
elucidate pivotal virulence factors for this destructive and toxic pathogen.  
Classical mutagenesis experiments were carried out in order to analyze which portion of 
the SpoIIE protein is crucial to retain the regulatory function it has on app expression. The two 
genes of interest were originally isolated from C. difficile strain VPI 10463, before transforming 
into E. coli (NEB 5-alpha) for subsequent experimentation.  Mutants of the SpoIIE gene were 
created by either endonuclease restriction digest or by PCR site-directed methods. The two genes 
of interest, appDF and SpoIIE, were transformed in E. coli UA321 and presented exclusively on 
their own plasmids (pUA321:appDF and pUA626:SpoIIE) in order to examine the changes in 
regulation observed between them (Figure 2.1.). Mutation targets within the SpoIIE gene were 
selected by using the Qiagen CLC genomics workbench, which also aided in primer design. Two 
categorical types of mutations were made: large deletions and missense point mutations. Targets 
for genetic mutations were chosen based on their predicted effect on overall SpoIIE protein 
assembly, folding, and function.  There are three post-translational interactions SpoIIE displays 
that served as central experimental targets:  integration of monomers, dimerization, and 
activation of phosphatase. The restriction digest experiment removed the portion of the gene 
coding for the transmembrane anchor; thought to be imperative for integration. This is a stretch 
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of approximately 100 hydrophobic amino acids in the truncated version of SpoIIE present on the 
pUA626 plasmid. Site-direct mutants contained missense mutations leading to the translation of 
incorrect amino acids, potentially essential for dimerization or phosphatase activation. The 
missense point mutations were also chosen because of the change in fundamental properties 
exhibited by the amino acids. Two mutants were created, D274K and D260Q. DK is shorthand 
for a missense mutation changing aspartic acid to lysine at position 274 going from charged, 
acidic to charged, basic. DQ is a mutation changing glutamine to aspartic acid at 260, changing it 
from uncharged to charged, acidic. It is important to note that these position numbers correlate to 
the truncated version of SpoIIE present on the pUA626 plasmid, and not the full SpoIIE found in 
databases. 
a) b)  
 
 
As a proxy measurement for expression of the ABC peptide transporter in the presence of 
mutant SpoIIE, the plasmid with app has an upstream construct containing the reporter gene, 
GFP (green fluorescence protein). When expressed under normal conditions, in the absence of 
SpoIIE, this construct brightly fluoresced as appDF was promoted. In the positive control, where 
SpoIIE was unmutated, appDF was repressed along with the upstream construct, therefore 
showing little to no fluorescence. A discerning range of fluorescence levels were expected to be 
observed in this assay.
Figure 2.1. Plasmid maps with (a) appDF and(b) SpoIIE genes 
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II.2. Materials and Methods 
II.2.1. General culturing methods 
Cultures of E. coli were grown in Luria Bertani (LB) growth media in the presence of 
carbenicillin (Cb), as the plasmids used carry the bla gene that makes them resistant; allowing 
for proper selection. Liquid media was made at 500mL per batch and carbenicillin was added 
post sterilization via autoclave, at a concentration of 50 ug/ml, denoted as Cb50. Initial stocks of 
cell cultures and plasmids were grown in 25 mL of media at 37°C overnight in a shaking 
incubator, with the incubation time ranging from 12-16 hours. Glass flasks with ventilated caps 
were used to allowed for proper aeration. These liquid cultures were then used to either create 
glycerol stocks to be kept at -80°C, or processed via mini plus™ plasmid DNA extraction system 
(Viogene) in order to serve as control stocks of plasmid, kept at -20°C.  
Plate culturing was performed on LB Cb plates, which were made in 500mL batches at a 
time, resulting in an average of 18 plates. Five-hundred microliters of Cb50 was added to the 
liquid media once cooling post autoclave sterilization. Plates were poured near open flame, 
allowed to set, and then stored at 4°C until used. Cultures of E. coli were spread onto LB Cb 
plates by first pipetting 50-100 µL of cell culture onto the plate surface and then streaking with a 
sterile loop, followed by incubation at 37°C overnight (12-16 hours).  
II.2.2. Plasmid DNA extraction 
Plasmid DNA extraction was performed as directed by the manufacturer protocol for mini 
plus™ plasmid DNA extraction system (Viogene) and the “spin method” was followed. This was 
done from either frozen stock of cell culture preserved in glycerol (800µL cell culture in 200µL 
80% glycerol) at -20°C or directly from cell culture post-incubation. After plasmid extraction, 
samples were evaluated via gel electrophoresis. Specific stocks were set aside as controls, not to 
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be mutated. The quality and quantity of plasmid DNA of the control stocks was evaluated with 
Qubit™ 2.0 (Invitrogen) spectrophotometry and noted. All plasmid stocks were kept at -20°C 
throughout the progression of the project. 
II.2.3. Gel electrophoresis 
Gel electrophoresis often served as a qualitative measurement throughout this work for 
various purposes. Five grams of 2% agarose gel with 4µL SYBR® Safe DNA Gel Stain 
(Invitrogen) was used and ran at 100V for an average of 25 minutes in 1X TAE buffer acquired 
from a community lab stock (Tris base 4.844 g/L, acetic acid 1.21 mL/L, EDTA 0.372 g/L). 
Additionally, 5 µL of DNA MW 1Kb ladder (VWR) used from an individual stock stored at RT 
(10 µL ladder, 20 µL 6X gel loading dye (NEB), 80 µL 1X TAE buffer). A control plasmid 
DNA sample was always present in the first well for comparison. 6X loading dye was used by 
preference, as loading the wells tended to be more successful with lesser volumes. Images of the 
gels were captured using Kodak Electrophoresis Documentation and Analysis System in 
combination with ULTRA-LUM, Electronic UV Transilluminator. The images were then 
evaluated through an EOS program paired with the Nikon camera on a shared laboratory desktop 
computer.  
II.2.4. Polymerase chain reaction (PCR) site-directed mutagenesis 
Multiple site-directed mutations were carried out through Polymerase Chain Reaction 
(PCR). Quantification via Qubit™ 2.0 (Invitrogen) spectrophotometry was necessary before 
beginning, as PCR protocols require known DNA concentrations (ng/µL). PCR site-directed 
mutagenesis was preformed via the NEB Q5 protocol, and the primers were designed via Qiagen 
CLC genomics workbench. Using the primers shown in Table 2.1., site-directed mutagenesis via 
PCR was employed to create missense point mutations within SpoIIE on plasmid pUA626 
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extracted from E. coli. Each PCR reaction was performed in 25 µL, comprised of 12.5 µL Q5 
hotstart high fidelity 2x mastermix (NEB), 1.25 µL of each F/R primer at a concentration of 10 
µM, 1 µL of 1-25 ng of the template DNA, along with nuclease-free water to bring each reaction 
to the 25 µL final volume. PCR amplification was done using Thermal cycler (MWG-Biotech) 
and the reaction conditions were denaturation at 98°C for 30s, 25 cycles for annealing at 98°C 
for 10s, 50-72°C for 10-30s, 72°C for 20-30s/Kb and extension at 72°C for 2 min. These 
conditions were taken from the NEB Q5 manufacturer’s protocol. 
 
Table 2. 1. Primers used for PCR site-directed mutagenesis 
Mutant Primers Sequence (5’à 3’) Source 
DK 
F 
R 
CTTATCTCAAAAGTTAGAAGGCG 
GATTTAATGGATTTTGAAATACTT 
Eurofins 
 
DQ 
F 
R 
AATAGCAAATGCGATAAGAAGTATTTCAAAATC 
AACTTTCTACTTTCTGAAAAC 
Eurofins 
 
*Primers designed using Qiagen CLC genomics workbench 
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II.2.5. Endonuclease restriction digest mutagenesis 
An additional method for mutagenesis was used for the aim of deleting the 
transmembrane anchor region of the SpoIIE gene. The endonucleases used for this experiment 
were Spe1 and Eco53KI, chosen with the aid of the Qiagen CLC genomics workbench. Two 
identical reactions were done in tandem, one to be used for gel electrophoresis evaluation. Ten 
microliter reaction volumes were used, consisting of 8µL of plasmid pUA626 with control 
SpoIIE, 1µL cutsmart® (NEB) 0.5µL of SPE1, 0.5µL of Eco53KI, incubated in the Thermal 
cycler (MWG-Biotech) 37°C for 1 hour. Following incubation, one of the reactions was run on a 
gel against control pUA626 with conditions listed above. If the gel showed successful digest, 
then the secondary reaction tube was treated with 1µL of VENT DNA polymerase (NEB) and 
1µL dNTP from a personal stock (10µL of A, T, C, G and 60µL of DI H2O) and incubated at 
72°C for 30 min followed by 3 min at 80°C. The step both inactivated the endonucleases and 
created blunt ends on the mutant plasmid. The reaction tube was then cooled to RT before adding 
1µL T4 DNA ligase (NEB) and 1µL polynuclear kinase (Promega), left to incubate overnight. 
 
 
Table 2. 2. Enzymes used in restriction digest mutagenesis 
Enzyme Restriction Site  Source 
Spe1 
A'CTAGT (5’à 3’) 
TGATC'A (3’à 5’) 
NEB 
 
Eco53KI 
GAG'CTC (5’à 3’) 
CTC'GAG (3’à 5’) 
NEB 
 
SpoIIE TM 
F: CCAGAGCGATTATTTAATAAG 
R: CTCGAGCTCGGATCCCCATCG 
Eurofins 
*Primers designed using Qiagen CLC genomics workbench 
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II.2.6. Mutant plasmid chemical transformation 
In both cases of mutagenesis (site-directed and restriction digestion) after confirmation of 
mutation success via gel electrophoresis, the new mutant plasmid was transformed into 
chemically competent E. coli cells. Initially, E. coli 10-Beta competent cells (NEB) were used 
but yielded low transformation efficiency at 1.5 x 106 cfu/µg. Accordingly, transformation 
experiments were then carried out with NEB C2987 chemically competent E. coli cells, resulting 
in a much higher efficiency. Transformations were performed following the Q5 site-directed 
mutagenesis protocol (NEB) for all mutants. After a 1-hour incubation of transformed, 
chemically competent E. coli cells at 37°C, two LB Cb plates per transformation were streaked. 
Each plate as a minimum (50µL) and maximum (100µL) acceptable amount as stated in the 
transformation protocol. The transformed E. coli cells were pipetted onto the plate near open 
flame, and then spread either with a sterile loop or L-spreader. These plate cultures were 
incubated at 37°C overnight. After receiving the new, highly efficient competent cells, it was 
found that 50µL yielded an ideal number of colonies, making that the standard amount used.  
 
II.2.7. Colony selection and broth cultures 
Following the incubation of the transformed chemically competent E. coli (NEB C2987) 
cells on LB Cb plates, colonies were selected to grow in liquid media for further processing. 
Approximately 6 colonies were picked with a sterile loop and individually inoculated into 4mL 
of LB Cb liquid media in glass test tubes. These test tube broth cultures were incubated for 12-16 
hours overnight at 37°C in a shaking incubator. Following incubation, 2mL of the cell culture 
was processed using mini plus™ plasmid DNA extraction system (Viogene). These highly 
concentrated mutant plasmid stocks were either immediately utilized or stored at -20°C for 
subsequent experiments. 
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II.2.8. Creation of electrocompetent E. coli stocks 
Commercially purchased chemically competent E. coli cells (NEB C2987) were used in 
mutant transformations, but the use of electroporation to create electrocompetent E. coli cells 
was necessary to observe the regulatory relationship in question. This is because the E. coli strain 
(pUA321) containing the plasmid with the app locus (peptide transport gene) is not store-bought, 
but rather developed by the Ivey lab. Therefore, it must be made electrocompetent via 
electroporation so that transformation of the plasmids containing the SpoIIE mutants (pUA626) 
yields a new E. coli UA321 strain where both plasmids are present (pUA321 and pUA626).  
E. coli UA321 was grown in liquid culture by inoculating 25mL Km50 LB broth with 
20µL of glycerol stock and then incubating for 12-16 hours at 37°C. Post-incubation, 1mL was 
used to inoculate 50mL LB broth with 50µL of Km50. This liquid culture was permitted to grow 
into late log phase, or until a Klett value of 100-150 was reached (approx. 4 hours). At this point, 
the culture was kept on ice along with 50mL centrifuge tubes, 10% glycerol stock, and sterile DI 
H2O. After multiple centrifugations (11,000rpm at 10 min) and rebalancing with sterile water, 
the pellet was suspended in 0.4mL of 10% glycerol, this then was divided up into approximately 
6 tubes of 100µL glycerol stocks to be kept at -80°C until transformation via electroporation. 
II.2.9. Mutant transformation to E. coli UA321 and fluorescence prep 
In order to evaluate the regulatory relationship observed between SpoIIE and app, the 
plasmids with mutant SpoIIE were then transformed into E. coli strain UA321, which contained 
the app locus on its own plasmid, pUA321. This transformation was carried out via 
electroporation. The electrocompetent E. coli cells were kept on ice, alongside other materials 
such as the cuvettes and cuvette holder. One-hundred microliters of electrocompetent E. coli 
UA321 plus 1µL of mutant plasmid pUA626 were shocked using the following settings: 1.5 kV, 
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200 ohms resistance, and 25microfarads capacitance, using Bio-Rad Gene Pulser™ and then 
allowed to incubate for an hour at 37°C in 1000mL of recovery media. 
After transformation, 50-100 µL cell culture was pipetted onto prewarmed Cb/ Km LB 
plates and then spread with a sterile L-spreader near open flame. 25 mL of Km25 was added to 
the Cb LB plates previously described, by spreading 10µL Km onto the plates’ surface 5 minutes 
before the introduction of the transformed electrocompetent E. coli UA321. Both antibiotics are 
used in this transformation because the plasmid with the SpoIIE mutant is resistant to Cb, while 
the plasmid containing the app locus is resistant to Km; therefore colonies present after 
incubation will contain both plasmids, as desired. The Cb/ Km LB plates were incubated at 37°C 
for 12-16 hours overnight. 
The next day, 4-6 colonies were selected to subculture and spread onto a subsequent Cb/ 
Km LB plate, and their size was noted. The new plate was sectioned off into six partitions and 
each selected colony was spread into a designated section, two of which were used for controls.  
The two controls (dim and bright) were streaked from freezer stocks previously cultured 
and transformed through methods mentioned above. The “bright” control was E. coli UA321 in 
absence of SpoIIE: no repression. While the “dim” control was E. coli UA321 in the presence of 
unmutated SpoIIE on pUA626: strong repression. The freezer stocks were thawed on ice and 
then a loopful was to be streaked onto the plate. After all picked colonies were streaked, the plate 
was to be incubated at 37°C for 12-16 hours before observing fluorescence.  
II.2.1. Evaluation of fluorescence 
Fluorescence was detected and recorded by using the Canon EOS Utility on a shared lab 
desktop Dell connected to a Cannon Rebel T4 camera. Blue light provided by 420 nm 
wavelength LED light strips was used for fluorescence excitatation. The sectioned plate, as 
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describe in the section above, was removed from incubation and placed with its lid off inside the 
viewing arena within the black box. The relative brightness was to be scored against the two 
controls. Note: fluorescence methods were only practiced with, no useable fluorescence data was 
collected. 
 
 
 
 
 
 
 
 
 
 
 
25 
II.3. Results 
II.3.1. Creation of C. difficile SpoIIE mutants 
After mutagenesis, the mutants DK and DQ were first evaluated via gel electrophoresis 
before further transformations were carried out. The mutated plasmid DNA was stored at -20°C 
with the intention of sending them for sequencing in order to confirm that they were successfully 
mutated in the manner intended. The endonuclease restriction digest mutant aimed at deleting the 
transmembrane anchor region proved to be trickier than the missense point mutations. The 
evaluation of this mutant via gel electrophoresis was expected to have yielded obvious results 
with such a large sequence missing. Many tactics were employed to try to get this restriction 
digest to work. Initially, new endonucleases were ordered in case the ones used from the freezer 
stocks were inactive. Second, the protocol outlined in the methods section was tinkered with 
numerous times, extending incubations or increasing various enzyme volumes. Third, specific 
PCR primers (instead of the endonucleases) were designed using the Qiagen CLC Genomics 
Workbench. These primers have not yet been tested because of the lab closures. 
II.3.2. Experimental progress 
Unfortunately, this portion of the project came to an abrupt halt and as a result, no 
concrete data was gathered for analysis of the mutants. In the early Spring of 2020, the 
University of Arkansas labs closed for non-essential research due to the on-going Covid-19 
pandemic which impacted many research projects, including this one. In light of the pandemic, a 
second research aim, and therefore third chapter, was pursued in order to supplement the loses 
exhibited in this section. The additional research aim was geared to be achieved in the absence of 
a laboratory and focused on computational modeling of the protein structures resultant of the 
genetic mutations outlined in this chapter. 
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II.4. Discussion 
As mentioned, the intentions of this research aim were to assess protein function 
following mutagenesis experimentation. The presence of GFP on the plasmid containing appDF, 
fundamentally provided a qualitative measurement of expression for appDF in the presence of 
mutated SpoIIE. The level of repression would parallel to the relative level of fluorescence 
produced by the E. coli colonies transformed with the modified plasmids. Having two controls, 
the “dim” and “bright” control, would have allowed for the comparison of the brightness 
exhibited by the mutants when streaked and grown upon the partitioned plate described. The 
experimental design for the creation of the C. difficile SpoIIE mutants required the exercise of 
many classical microbiology and molecular biology techniques, but the lack of data collected 
proved to be disappointing.  
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II.5. Conclusion 
The in vitro goals pursued in this research project ultimately lack conclusive evidence to 
either support or reject the stated hypothesis. The absence of results is not due to experimental 
failure, but rather external and circumstantial reasons. This leaves room for incoming graduate 
researchers to confidently complete this mutagenesis assay, which will be discussed in Chapter 
IV: Future Directions. 
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III. COMPUTATIONAL MODELING OF SPOIIE STRUCTURE 
III.1. Introduction 
A growing number of biological sciences are beginning to fundamentally incorporate and 
rely on in silico techniques to substantiate in vitro results. The structural modeling of proteins is 
an example of how computational techniques provide unique visual representations of molecular 
interactions otherwise limitedly studied in the lab. Three-dimensional images of proteins can aid 
in the visualization of complex interactions. These images show secondary protein structures 
such as helices or sheets, and their resulting tertiary arrangement (Bienert et al., 2017; Martí-
Renom et al., 2000). Being able to conceptualize these structures elucidates the mechanisms 
underlying enzymatic events such as active site binding and protein-protein interactions. 
Modeling of structurally unknown or “target” proteins is done by taking the DNA 
sequence data or the primary amino acid sequence and aligning it with the sequence of a 
structurally similar template (Martí-Renom et al., 2000). This predictive technique is known as 
homology or comparative modeling. The quality and accuracy of the structures generated 
through homology modeling is dependent upon the sequence identity between the target and the 
template. Alignments with low E-values signify that the template and target protein are closely 
evolutionarily related (Martí-Renom et al., 2000). Protein tertiary structures are more conserved 
than DNA sequences, and a sequence identity above 20% is ideal and renders significantly 
similar protein structures that share similar properties (Martí-Renom et al., 2000; Chothia & 
Lesk 1986).  Inaccuracies in homology modeling are derived from initial errors in template 
selection and alignment, so the choice of template is a crucial step.  
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In this study, SpoIIE from the analogous model organism, Bacillus subtilis is used as the 
template, as this protein structure is known. The phosphatase domain (C’ terminus) of SpoIIE 
has previously been crystallized and the structure is readily available in online protein databases 
(PDB) to use as the template. After the production of the target C. difficile SpoIIE phosphatase 
domain, models of the unknown central domain and N’-terminus TM domain were created 
through non-template threading, which is a method that produces models based off structural 
homologs in the PDB, rather than relying purely on sequence similarity. This created a novel 
structure comprised of all three protein domains. 
Prior to the creation of this complete SpoIIE model, multiple algorithms were assessed 
and compared for their initial sequence alignment and the resulting models. This was done by 
comparing sequence identity, model quality estimates, clash values, and then the side-by-side 
visualization of the model variants. Additionally, after the webservices were analyzed, preferred 
ones were chosen to model the target C. difficile SpoIIE mutants. Qualitative conclusions based 
upon the structural models are discussed in this section.  
 
Figure 3.1. Primary sequence: C. difficile SpoIIE, UA001 
*Image created using Qiagen CLC Genomic Workbench 
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III.2. Materials and Methods 
III.2.1. Sequence alignment and template selection 
 The first step in homology modeling is to find a suitable template from which the 
predictive model is based. The template was predicted to be that of B. subtilis SpoIIE, as it is 
comparatively used in countless studies paralleled to C. difficile. Despite this projection, the 
primary sequence, or FASTA file, of the lab’s truncated SpoIIE was BLAST against multiple 
databases in order to confirm a reliable template was used for homology modeling. This step was 
done in combination with modeling as the web servers used are full pipelines, preforming all 
required steps to produce a model. The sequence identities derived from these searches are 
reported in Results. As an additional independent search, a BLAST was run against the EMBL 
(European Molecular Biology Laboratory) database, which yielded similar top results of B. 
subtilis SpoIIE strain 168 with a sequence identity of 27.5% and an E-value of 3.5e-50. Sequence 
identities must be above 20% in order to use homology modeling. The sequence coverages are 
almost entirely for the phosphatase domain, whose crystal structure exists in the PDB. Across 
multiple services, this domain’s coverage was upwards of 95%. 
III.2.2. Modeling programs 
 Multiple bioinformatics software services, accessed through free online servers, were 
used to develop structural models of C. difficile SpoIIE through homology modeling against a B. 
subtilis template. Each of the websites used have their own algorithms, which allowed for 
comparison of scores and model constraints. The websites used were Swissmodel, Phyre and 
Robetta. After the modeling softwares were analyzed for their respective capabilities, the 
structural mutants were then modeled and compared. 
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III.3. Results 
III.3.1. Homology modeling 
The FASTA sequences of C. difficile SpoIIE (Appendix Figure A 1.) and B. subtilis 
(Appendix Figure A 2.) were aligned. The sequence for B. subtilis is notably longer, because as 
mentioned in Chapter 2, the C. difficile SpoIIE sequence from pUA626 is truncated and missing 
a little over 200 amino acids from the complete TM sequence. The C. difficile SpoIIE FASTA 
consists of multiple domains, of which the C’-terminus or phosphatase domain is the most 
studied. In order from N’à C’ the sequence shows ~4 TM helices, a linker region, an alpha-
helix, and the regulatory and catalytic phosphatase domains (PPM). The sequence -LDYD- in the 
C. difficile SpoIIE FASTA signifies the beginning of the phosphatase domain. When preforming 
homology modeling, the FASTA sequence was cut after -LDYD- at amino acid number 245, in 
order to report the highest coverage and confidence level. This begins the phosphatase domain, 
which has previously been crystallized and the X-ray crystallization structure data is available in 
these databases to use as the template for the C. difficile SpoIIE being studied in this project. The 
reported coverages after cutting the FASTA at amino acid 245, were all over 95%, which is ideal 
for homology modeling. 
Three bioinformatic programs were used: Swissmodel, Robetta, and Phyre. These are all 
full pipeline webservices, meaning that they not only find a suitable template, but also execute a 
pairwise sequence alignment with the target, and produce the resultant homology model. These 
algorithms also report model evaluation values assessing their quality and constraints, which 
were considered before continuing on with mutation modeling.  
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The homology models from Swissmodel, Robetta and Phyre of the phosphatase domain 
appear nearly identical, which is a nice visual validation for algorithm accuracy. These images 
are shown side-by-side in Figure 3.2. It is important to note that the model produced by Phyre is 
not dimerized like the other two images. Numerically, the models prove to be similar as well, 
with identical sequence similarity, coverage, and confidence levels. The homology modeling of 
the SpoIIE phosophatase domain is reliable and was preformed with ease due to the presence of 
the B. subtilis homolog in the PDB. 
 (a) (b)  
(c)  
Figure 3.2. C. difficile SpoIIE phosphatase domain: Swissmodel (a), Robetta (b), Phyre (c) 
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After modeling the phosphatase domain, the N’-terminus or truncated TM region (first 
100 amino acids) was also homology modeled through Phyre (Figure 3.3.) The generated image 
looks exactly as expected, with four TM helices. Interestingly, the template used for this target 
sequence was a thiamine binding protein with 25% sequence similarity. Phyre modeled 72% 
(coverage) of the TM region FASTA sequence with 94.3% confidence. Phyre was chosen as the 
program for this homology model as the job was completed the fastest, and created the best 
visual representation. 
  
 
After creating the initial homology models, the phosphatase domain was further 
evaluated using Phyre, and the analyses are shown in Figure 3.4. Phyre2 and SuSPect are 
investigative sister programs that have the ability to assess point mutation effect on structure (a), 
the potential for steric clashes (b), as well as provide a Ramachandran analysis (c). The coloring 
scheme of the models below show red as indicating the most problematic points.  
Figure 3.3. C. difficile SpoIIE transmembrane 
domain: Phyre 
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The reports generated and shown in Figure 3.4 reflect the missense mutations outlined in 
Chapter 2. Image (d) is of amino acid 260, specifically looking at mutant DQ, while image (e) 
specifically shows amino acid 274, or mutant DK. These bar graphs show which point mutations 
are likely to be the most deleterious at the indicated point in the FASTA sequence. By 
comparison, Phyre is predicting the DQ point mutation to be more likely to affect protein 
function than the DK mutation.  
 (a) (b) (c)  
(d) (e)  
Figure 3.4. C. difficile SpoIIE phosphatase domain analysis: Phyre2/SuSPect 
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III.3.2. Mutant SpoIIE structural models  
After the primary homology modeling was done through multiple servers, mutant models 
were then created based upon the point mutations outlined in Chapter 2. The mutant models were 
created using Phyre, because of the additional capabilities of Phyre2 and SuSPect, as previously 
mentioned. Mutants models were made by manually changing the FASTA sequence before 
running the program. As shown in Figure 3.5. and 3.6. the structural conformation of the SpoIIE 
phosphatase domain does not appear to change because of the point mutations. As an interesting 
way to double check these mutants, the residue preference at these specific points was analyzed 
and showed high preference towards the original amino acid. This bar graph is reported next to 
the corresponding mutant model. 
The TM mutant was not modeled because it cannot be evaluated for loss of function in the 
same manner as the point mutations. The TM mutation is very different in nature and should 
fundamentally be evaluated in vitro. 
  
Figure 3.5. C. difficile SpoIIE DK mutant model: Phyre2 and SuSPect 
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Figure 3.6. C. difficile SpoIIE DQ mutant model: Phyre2 and SuSPect 
Importantly, Phyre only shows SpoIIE as a monomer and the point mutations being 
analyzed are on the alpha-helix. This alpha-helix is known to serve as the dimer interface, so 
questions were raised as to whether or not these point mutations could be affecting dimerization. 
This is a functional flaw of the Phyre program, as the mutant models appeared to not have 
conformational changes existing as a monomer, but could very well show differences after 
forming a dimer.   
III.3.3. Non-template threading 
In addition to homology modeling, the webservice, Robetta, has a higher predictive 
capability in the sense that it can construct non-template models through threading and fold-
recognition programming. Robetta was able to predict the structure of the full FASTA sequence, 
and not just phosphatase domain. Threading programs have the unique ability to produce models 
with or without sequence similarity; template-free. These types of alorithms search the PDB for 
structural homologs and folding pattern similarities rather than just relying on sequence 
similarity.  
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This created a novel model of C. difficile SpoIIE, spanning the entire truncated lab 
version of SpoIIE. There is no comparative structural protein data on the SpoIIE central linker/ 
switch domain via NMR or X-ray crystallization, so the algorithm made its modeling predictions 
based off the target FASTA sequence and structural homologs in the PDB. This method is 
structurally not the most reliable, but the generated model is shown in Figure 3.9. The reported 
confidence level is 57%. The TM region is depicted in purple, the linker/ central domain in blue, 
and the phosphatase domain spans green through red. The phosphatase domain is recognizably 
similar in this model to the other homology models shown in this chapter. It can be assumed that 
a large portion of the 57% confidence level is due to the data available on the phosphatase 
domain, which accounts for over half of the structural model.  
Interestingly, the TM membranes modeled by this program do not show the four TM 
helices as one would predict these hydrophobic regions to appear. Robetta shows the truncated 
TM SpoIIE gene fragment to possibly be encoding a soluble, dimeric form of SpoIIE. This is 
highly speculative, but if this model is correct then the soluble form of SpoIIE could be isolated 
and crystallized. This hopeful find for the lab is discussed in Future Directions. 
 
Figure 3.9. C. difficile SpoIIE complete model: Robetta 
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III.4. Discussion 
Protein structure determination through experimental methods such as NMR (nuclear 
magnetic resonance) or X-ray crystallography is time-consuming and costly, but newer, 
progressive techniques have taken main stage as computational modeling further develops. 
Knowledge based methods like homology modeling are increasing popular and provide an 
efficient alternative to determining protein structures.  
The modeling of C. difficile SpoIIE exhibited in this study confidently depicts the 
phosphatase domain through homology modeling with a template structure derived from B. 
subtilis SpoIIE. Across all webservices used for homology modeling, the confidence level was 
above 95%. The TM region was also accurately modeled, portraying four transmembrane 
helices, as expected. The SpoIIE gene used in these experiments was known to be the truncated 
version, having just four of the ten TM helices. Comparatively, Robetta modeled this same TM 
region quite differently, showing a cluster of helices in a formation not observed in highly 
hydrophobic domains. 
In order to model the central linker domain of C. difficile SpoIIE, a different approach had 
to be taken as there is no template data available for homology modeling. The program Robetta 
was used to model this region template-free through protein threading. This developed a 
complete predicted image of SpoIIE. This model was made by an algorithm that searches the 
PDB for folding and structural homologs in order to develop a comparative model for the 
portions of the target sequence lacking a homologous template sequence. 
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After SpoIIE was modeled through various methods, the point mutations outlined in 
Chapter 2 were evaluated by Phyre. According to Phyre, the point mutation denoted as DQ is 
likely to have a deleterious effect on protein function. Excitingly, this can be tested for appDF 
repression in vitro upon lab reopening by completing the fluorescence assay. Contrastingly, the 
DK mutant is not projected to effect function to the same extent. These predictions are an 
exciting way to visualize the effects of the PCR site-directed mutagenesis experiments discussed 
in Chapter 2. The relative fluorescence levels in vitro may mirror this prediction, where for 
example, the lesser effect on function in the DK mutant may still fluoresce at a level similar to 
the dim control as this SpoIIE mutant may still functionally repress appDF. 
Alternatively, Phyre was unable to predict conformational changes that may occur once 
the monomeric form of SpoIIE is dimerized. This disadvantage can be overcome by further 
structural investigation by other mutant modeling programs, and is an example of how the 
preferred modeling program to use ultimately depends on the purpose and goal of the project. 
As shown by modeling the mutations done in vitro, each program used and their 
respective algorithms have their advantages and disadvantages. Modeling of protein structure is a 
useful method for investigating unknown relationships, such as the repression of appDF by 
SpoIIE, as understanding structure is often the first step to understanding function. 
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III.5. Conclusion 
The data presented through computational modeling of mutant SpoIIE elucidates the 
experimental mutagenesis effect on protein function. The greatest effect on function should be 
seen in the DQ mutant, where aspartic acid is translated rather than glutamine. Comparatively, 
the DK mutant is projected to have a lesser effect on SpoIIE protein function. The mutation 
analysis program that was used in this study produced a spectrum of predictive effects. This has 
the potential to mirror the spectrum of relative brightness as would be seen in the fluorescence 
assay. It could be that the DK mutant may fluoresce to a level brighter than the DQ mutant, but 
dimmer than the “bright” control. The computational analyses done in this project could 
effectively complement and substantiate fluorescence data. 
It must be noted that the predicted mutational effects simply project whether a mutation 
has a statistical probability of interfering with protein function, but do not have the capacity to 
forecast which function. This leaves ambiguity as SpoIIE is a multifunctional protein. If the 
fluorescence assay results do not match the computational predictions, then this project could 
provide insight into SpoIIE function beyond appDF repression or involvement in peptide 
transport. Both point mutations were located on the cytoplasmic alpha-helix which is known to 
be involved in the timing and regulation of the phosphatase domain activity. This long alpha 
helix serves as the dimer interface, so if the DK or DQ mutations happen to interfere with 
dimerization, then an entire cascade of sporulation events may be inhibited. 
Regardless of the outcome for future experimentation, the protein modeling of C. difficile 
SpoIIE has proven to be a useful tool and could aid in furthering the holistic understanding for 
the pathogenicity and virulence factors of this infectious disease.  
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IV. FUTURE DIRECTIONS 
In light of the results presented from both of the stated research aims, future investigation 
into this topic may take three presumable routes. The first is quite simple, in that incoming 
graduate researchers could finish the mutagenesis fluorescence assay. The techniques used are 
known to be successful by previous students and all materials are abundantly present in the lab. 
In addition to evaluating the mutants from this project, future students could also create new 
ones. The qualitative fluorescence data to be gathered, may also be interpreted in light of the 
structural models created and discussed in this research project. It is expected that application of 
these visual structures may bolster future lab projects reliant on in vitro experiments. 
Second, it should be investigated as to how these proteins are interacting specifically 
within E. coli. SpoIIE is a multifunctional protein, and it should be assumed that it is 
dynamically interacting with many other proteins. This scenario must always be considered 
when not working in the native cell, here being C. difficile. For instance, it is known that the 
SpoIIE C-terminal cytoplasmic domains carry out specific binding to cytoskeletal proteins such 
as FtsZ, RodZ, and others (Ben-Yehuda & Losick 2002; Lucet et al., 2000). In the analogous 
system Bacillus subtilis, SpoIIE interacts with FtsZ and Rodz to aid in spore septum formation, 
but these interactions are far from understood (Arigoni et al., 1999; Ben-Yehuda & Losick 2002; 
Lucet et al., 2000). FtsZ is present in E. coli, so it can be inferred that SpoIIE is involved in 
multiple regulatory relationships, not just the one with app focused on in this study. The 
structural models of the SpoIIE protein presented in this project, could be applied to further 
proteomic studies ideally investigating how transformation to competent E. coli affects this novel 
relationship between SpoIIE and app, in the presence of other proteins such as FtsZ. 
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Lastly, if the model produced by Robetta is correct, then the SpoIIE gene fragment used 
experimentally in the Ivey lab may be encoding a soluble form of the SpoIIE protein, which is 
normally membrane bound by the hydrophobic N’-terminus transmembrane region.  This freely 
dispersed, soluble form of SpoIIE could then be isolated, purified, and crystallized. This is an 
exciting possible future direction for the lab as the crystal structure for C. difficile SpoIIE is 
presently unknown. Ultimately, the work presented in this thesis may contribute to may future 
research projects and potential directions for the Ivey lab.
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VI. APPENDIX 
STVLILLTSIVGGATMGASSGVIIGVASILNNMTSAVYMGIYSFSGLISGAFNKINKYFCIL
GYILSWTIIYLYTSGITSNMMQLRDILLGCLIVLVLPERLFNKIEKLIKSNVASNEIVYDYI
MRSKNLTNSRLNSIYKTYDDLADTFDKIREKDKVLDQRDIANVIDMIHNDECKSCSMRR
MCWESRFNHTYTMVYNILEKIEEKGELSLNDIPKNFRKECMKPESIVKISNHYYKMFVL
DYDWSVKFSESRKLIANQIRSISKSIKSLSQDLEGDIMLDIEKEKNIYEQLERYDITVDKVS
YLTKSNSEFEISIEKKTCHDGCMCEDKIVNIISDLVGENMSVRKIGCHCLGGKCKATFVK
SQKYKAVTEVSAMSRDGHILCGDNYTYMEINDGKYMMAISDGMGKGKKAYEESSATI
DILEKMIDAKIKDEIVIDTINNMLLLKSSEEMFSTLDLGILDLKRGCLETIKMGACSTYIKR
EDGEVDLISSSSLPVGILSDVKIDRKNVKVKEGDYVIMVSDGIVDAGRNNNLGDNWLIY
FLKNIETTNPKEISNLILDRALELQALQI 
Figure A 1. FASTA Sequence C. difficile SpoIIE, UA001 
 
 
MEKAERRVNGPMAGQALEKLQSFFNRGTKLVTHHLHSLFFYKGFIYVVIGFLLGRAFIL
SEVLPFALPFFGAMLLIRRDKAFYAVLAVLAGALTISPKHSLLILAALLAFFVFSKVAAFI 
TDDRVKALPIVVFFSMAAARAGFVYAQNGVFTTYDYVMAIVEAGLSFILTLIFLQSLPIF 
TVKKVKQSLKIEEIICFMILIASVLTGLAGLSYQGMQAEHILARYVVLSFSFIGGASIGC 
TVGVVTGLILGLANIGNLYQMSLLAFSGLLGGLLKEGKKAGAAIGLIVGSLLISLYGEGS 
AGLMTTLYESLIAVCLFLLTPQSITRKVARYIPGTVEHLQEQQQYARKIRDVTAQKVDQF 
SNVFHALSESFATFYQASDEQTDDSEVDLFLSKITEHSCQTCYKKNRCWVQNFDKTYDL
MKQVMLETEEKEYASNRRLKKEFQQYCSKSKQVEELIEDELAHHHAHLTLKKKVQDSR
RLVAEQLLGVSEVMADFSREIKREREQHFLQEEQIIEALQHFGIEIQHVEIYSLEQGNIDIE
MTIPFSGHGESEKIIAPMLSDILEEQILVKAEQHSPHPNGYSHVAFGSTKSYRVSTGAAHA 
AKGGGLVSGDSYSMMELGARKYAAAISDGMGNGARAHFESNETIKLLEKILESGIDEKI
AIKTINSILSLRTTDEIYSTLDLSIIDLQDASCKFLKVGSTPSFIKRGDQVMKVQASNLPI 
GIINEFDVEVVSEQLKAGDLLIMMSDGIFEGPKHVENHDLWMKRKMKGLKTNDPQEIA
DLLMEEVIRTRSGQIEDDMTVVVVRIDHNTPKWASIPVPAIFQNKQEIS 
Figure A 2. FASTA Sequence B. subtilis SpoIIE 
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Figure A 3. Plasmid map pUA626 with SpoIIE: close-up 
 
 
 
Figure A 4. Depiction of SpoIIE domains 
